iRhoms: A Potential Path to More Specific Therapeutic Targeting of Lupus Nephritis

Lupus nephritis (LN) affects 30% to 60% of patients with systemic lupus erythematosus (SLE) and remains an intractable problem. Despite modern immunosuppressive strategies, <50% of patients reach complete remission. Many of the newer biologic agents tried to date have had no significant effect (reviewed in1). Novel treatments are clearly needed to protect kidneys against podocyte, endothelial, and tubule cell injury in SLE, which mainly occurs as a response to immune complex deposition.

https://ift.tt/2M5867I